Cargando…
Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study
BACKGROUND: GSK2190915 is a high affinity 5-lipoxygenase-activating protein inhibitor being developed for the treatment of asthma. The objective of this study was to evaluate GSK2190915 efficacy, dose–response and safety in subjects with persistent asthma treated with short-acting beta2-agonists (SA...
Autores principales: | Follows, Richard MA, Snowise, Neil G, Ho, Shu-Yen, Ambery, Claire L, Smart, Kevin, McQuade, Barbara A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732081/ https://www.ncbi.nlm.nih.gov/pubmed/23682661 http://dx.doi.org/10.1186/1465-9921-14-54 |
Ejemplares similares
-
Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
por: Singh, Dave, et al.
Publicado: (2013) -
Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice
por: Bakerly, Nawar Diar, et al.
Publicado: (2022) -
Use of Propranolol Blockade to Explore the Pharmacology of GSK961081, a Bi-Functional Bronchodilator, in Healthy Volunteers: Results from Two Randomized Trials
por: Norris, Virginia, et al.
Publicado: (2014) -
Tolerance and rebound with zafirlukast in patients with persistent asthma
por: Reid, David W, et al.
Publicado: (2008) -
Association of 5-lipoxygenase gene polymorphisms with bronchial asthma
por: BAI, CHUNYING, et al.
Publicado: (2012)